News report 📈 Stocks 🌍 United States

ImmunityBio Shares Rally 9.94% Following Founder Meeting with Erdogan

ImmunityBio shares surged nearly 10% on Tuesday as a high-profile meeting between founder Dr. Patrick Soon-Shiong and Turkish President Erdogan signaled potential growth for the company's cancer drug, Anktiva, in the region.

📅 September 23, 2026 🕐 1 min read

1 assets impacted. Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: IBRX ↑ 7/10 (60% confidence).

📊 Affected Assets (1)

IBRX

Bullish 🤖 60%

📅 Short-term 🌍 US · Explicit

Shares climbed 9.94% to $9.29 after founder met Turkish President Erdogan, fueling optimism about the company's expansion into Turkey and driving investor buying.

🎯 Key Takeaways

ImmunityBio shares closed at $9.29, up 9.94%, following positive sentiment from a high-level meeting in Turkey.
The company is aggressively expanding the reach of its FDA-approved bladder cancer drug, Anktiva, which is currently accepted in 34 countries.
Institutional interest remains strong, with hedge fund holdings in IBRX increasing by 62.6% to $314.9 million in the second quarter.

📝 Executive Summary

ImmunityBio Inc. shares climbed 9.94% to $9.29 after founder Dr. Patrick Soon-Shiong met with Turkish President Recep Tayyip Erdogan. The meeting fueled investor optimism regarding the company's expansion into Turkey for its FDA-approved cancer immunotherapy, Anktiva.

❓ FAQ

Why did ImmunityBio shares rise on Tuesday?

Shares rose following a meeting between founder Dr. Patrick Soon-Shiong and Turkish President Recep Tayyip Erdogan, which investors interpreted as a positive signal for the company's expansion into the Turkish market.

What is the primary product driving ImmunityBio's growth?

The company's primary growth driver is Anktiva, an FDA-approved immunotherapy medication used to treat specific types of non-muscle invasive bladder cancer.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article